The RIDASCREEN® UST Monitoring is an enzyme linked immunosorbent assay intended for the quantitative determination of ustekinumab (UST, Stelara®) in human serum and plasma.
Ustekinumab (UST, Stelara®) is a fully human monoclonal antibody that binds to the p40 subunit common to IL-12 and IL-23 thereby preventing the interaction with the cytokine receptors on T cells, natural killer cells and antigen-presenting cells.UST has been approved for treatment of moderate to severe Crohn’s disease (CD), plaque psoriasis and psoriatic arthritis.
The RIDASCREEN® UST Monitoring and our other TDM assays are vital to personalize treatment of patients to achieve better therapeutic targets.
- CE-marked version of the ELISA tests of KU Leuven
- Highly specific antibodies
- Ready to use reagents
- Validated for use on automated ELISA systems, e.g. the Dynex DSX®
|Test format||Microtiter plate with 96 wells (12 strips with 8 removable wells each)|
|Incubation time||1 h 40 min|
we have started to provide the documents for our products in an electronic format. These are the Instructions for Use (IFU), the Safety Data Sheets (SDS) and the Certificate of Analysis (CoA). For batches placed on the market after 01 January 2023, you can find our documents on the eIFU portal eifu.r-biopharm.com.